BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Phase 3

Active, not recruiting

Conditions: Hepatocellular Carcinoma
Liver Cancer

Interventions: Biological: Nivolumab
Other: Placebo

First Posted Date: 2017-12-26

Last Posted Date: 2023-11-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 545

Registration Number: NCT03383458

Locations: 🇺🇸
Local Institution - 0009, Atlanta, Georgia, United States
🇦🇺
Local Institution - 0220, Herston, Queensland, Australia
🇺🇸
Local Institution - 0272, Austin, Texas, United States

and more 172 locations

Observational Study for Lung Cancer Patients Treated With Nivolumab

Completed

Conditions: Lung Cancer

Interventions: Other: Non-Interventional

First Posted Date: 2017-12-26

Last Posted Date: 2022-05-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1462

Registration Number: NCT03382496

Locations: 🇫🇷
Local Institution, Fontaine Les Dijon, France

A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BMS-986205 reference tablet
Drug: BMS-986205 tablet with free base

First Posted Date: 2017-12-19

Last Posted Date: 2018-02-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT03378310

Locations: 🇺🇸
PPD Austin Clinic, Austin, Texas, United States

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

Phase 1

Completed

Conditions: Colorectal Cancer
Colorectal Neoplasm
Colorectal Tumors
Colorectal Carcinoma

Interventions: Biological: Nivolumab
Drug: Regorafenib
Drug: Trametinib
Biological: Ipilimumab

First Posted Date: 2017-12-19

Last Posted Date: 2024-12-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 325

Registration Number: NCT03377361

Locations: 🇺🇸
Local Institution - 0111, Miami, Florida, United States
🇨🇱
Local Institution - 0118, Santiago, Región Metropolitana De Santiago, Chile
🇺🇸
Local Institution - 0002, Madison, Wisconsin, United States

and more 44 locations

A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: belatacept

First Posted Date: 2017-12-15

Last Posted Date: 2019-07-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 84

Registration Number: NCT03375138

Locations: 🇺🇸
PPD Austin Clinic, Austin, Texas, United States
🇺🇸
Covance, Inc., Dallas, Texas, United States

A Study to Evaluate the Bioavailability of BMS-986205

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986205

First Posted Date: 2017-12-15

Last Posted Date: 2018-06-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 7

Registration Number: NCT03374228

Locations: 🇬🇧
Quotient Clinical, Nottingham, Ruddington Fields, United Kingdom

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Biological: Nivolumab
Biological: BMS-986249
Biological: Ipilimumab

First Posted Date: 2017-12-11

Last Posted Date: 2024-12-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 607

Registration Number: NCT03369223

Locations: 🇦🇺
Local Institution - 0025, Frankston, Victoria, Australia
🇨🇦
Local Institution - 0056, Ottawa, Ontario, Canada
🇮🇹
Local Institution - 0020, Napoli, Italy

and more 42 locations

Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens

Completed

Conditions: Hepatitis C

Interventions: Other: Non-interventional

First Posted Date: 2017-12-08

Last Posted Date: 2020-06-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 199

Registration Number: NCT03366610

Locations: 🇨🇳
Local Institution, Beijing, Beijing, China

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

Phase 1

Terminated

Conditions: Cancer

Interventions: Biological: BMS-986277
Biological: Nivolumab

First Posted Date: 2017-12-06

Last Posted Date: 2020-12-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 10

Registration Number: NCT03363776

Locations: 🇨🇦
Local Institution, Ottawa, Ontario, Canada
🇺🇸
Sanford Research, Sioux Falls, South Dakota, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: BMS-986177

First Posted Date: 2017-12-05

Last Posted Date: 2018-03-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT03362437

Locations: 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy